Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effect of Gefapixant on Cough-related Brain Activity in Patients With Chronic Cough
Sponsor: Stuart Mazzone
Summary
Recently, a new drug called Gefapixant passed phase III clinical trials for cough suppression in patients with chronic cough. The goal of this clinical trial is to investigate the effect of acute and prolonged administration of the drug Gefapixant on cough-related brain activity in patients with chronic cough. The main question it aims to answer is: does the mechanism of action of Gefapixant on the brainstem and brain circuits regulating cough differ between acute and prolonged therapy in people with chronic cough? Participants have their brain activity and their sensitivity to cough-inducing substances measured as well as complete questionnaires about their cough before and while taking daily Gefapixant.
Official title: The Effect of Acute and Prolonged Administration of Gefapixant on Cough-related Brain Activity in Patients With Chronic Cough
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
31
Start Date
2024-01-01
Completion Date
2026-06-30
Last Updated
2024-05-09
Healthy Volunteers
No
Conditions
Interventions
Gefapixant
Purinergic (P2X3) Receptor antagonist. Film-coated tablet taken orally.
Locations (1)
The University of Melbourne
Parkville, Victoria, Australia